These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11236625)

  • 21. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.
    Caro JJ; Getsios D; Raggio G; Caro G; Black L
    Headache; 2001 May; 41(5):456-64. PubMed ID: 11380643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naratriptan: an alternative for migraine.
    Dulli DA
    Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.
    Chen LC; Ashcroft DM
    Headache; 2007 Sep; 47(8):1169-77. PubMed ID: 17883521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
    Zhang L; Hay JW
    CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Almotriptan: pharmacological differences and clinical results.
    Pascual J
    Curr Med Res Opin; 2001; 17 Suppl 1():s63-7. PubMed ID: 12463281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study.
    Cabarrocas X; Esbri R; Peris F; Ferrer P
    Headache; 2001 Jan; 41(1):57-62. PubMed ID: 11168604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
    Deleu D; Hanssens Y
    J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
    Diener HC; Gendolla A; Gebert I; Beneke M
    Eur Neurol; 2005; 53 Suppl 1():41-8. PubMed ID: 15920337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan.
    Colman SS; Brod MI; Krishnamurthy A; Rowland CR; Jirgens KJ; Gomez-Mancilla B
    Clin Ther; 2001 Jan; 23(1):127-45. PubMed ID: 11219473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of almotriptan in controlled clinical trials.
    Mathew NT
    Eur Neurol; 2005; 53 Suppl 1():29-33. PubMed ID: 15920335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.
    Lofland JH; Nash DB
    Pharmacoeconomics; 2005; 23(3):259-74. PubMed ID: 15836007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan.
    Wang JT; Barr CE; Goldfarb SD
    Headache; 2002 Jan; 42 Suppl 1():38-43. PubMed ID: 11966863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.
    Sculpher M; Millson D; Meddis D; Poole L
    Pharmacoeconomics; 2002; 20(2):91-100. PubMed ID: 11888361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral almotriptan: practical uses in the acute treatment of migraine.
    Dowson AJ
    Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study.
    Massiou H; Pradalier A; Donnet A; Lanteri-Minet M; Allaf B
    Eur Neurol; 2006; 55(4):198-203. PubMed ID: 16772716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Almotriptan versus rizatriptan in patients with migraine in Spain.
    Leira R; Dualde E; del Barrio H; Machuca M; López-Gil A;
    Headache; 2003; 43(7):734-41. PubMed ID: 12890128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute management of migraine: triptans and beyond.
    Diener HC; Limmroth V
    Curr Opin Neurol; 1999 Jun; 12(3):261-7. PubMed ID: 10499171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analyses of cost-effectiveness of migraine therapies should consider multiple measures.
    Silberstein SD
    J Manag Care Pharm; 2003; 9(3):279-80; author reply 280-1. PubMed ID: 14613476
    [No Abstract]   [Full Text] [Related]  

  • 39. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
    Diener HC
    Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.
    Pascual J; Falk RM; Piessens F; Prusinski A; Docekal P; Robert M; Ferrer P; Luria X; Segarra R; Zayas JM
    Cephalalgia; 2000 Jul; 20(6):588-96. PubMed ID: 11075844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.